Shares of Catalyst Pharmaceuticals Inc. dove 49.2 percent on Tuesday after the company reported that the FDA will require it to submit positive results from an additional study of Firdapse (amifampridine phosphate) in patients with the rare autoimmune disorder Lambert-Eaton myasthenic syndrome (LEMS) prior to accepting its new drug application (NDA).